KLHL37 counteracts the FBXW7-induced degradation of N-Myc and enables the progression of neuroblastoma, indicating that inhibiting KLHL37 with RTA-408 could be a potential therapeutic strategy. The gene discussed is MYCN; the disease is neuroblastoma.